Full Breakdown
GLP-1 Medications Linked to Increased Risk of Osteoporosis and Gout
3/8/2026, 4:33:29 AM
Overview of the Findings
Recent research has raised concerns regarding the long-term bone health of older adults using GLP-1 medications, such as Ozempic and Wegovy, which are commonly prescribed for type 2 diabetes and obesity. A study published in the Journal of Clinical Endocrinology & Metabolism found that older adults with type 2 diabetes who began using GLP-1s had an 11% higher risk of fragility fractures compared to those on other diabetes treatments. This observational study followed over 46,000 adults aged 65 and older for nearly three years, indicating a statistically significant increase in fracture risk associated with GLP-1 use.
Key Statistics on Bone Health Risks
In addition to the fracture risk, a separate analysis presented at the American Academy of Orthopaedic Surgeons' annual meeting indicated that GLP-1 users had a 29% higher relative risk of developing osteoporosis over five years. Specifically, about 4.1% of GLP-1 users developed osteoporosis compared to 3.2% of nonusers. Gout was also reported more frequently among GLP-1 users, with 7.4% affected compared to 6.6% of nonusers, reflecting a 12% relative increase.
Mechanisms Behind the Risks
Experts suggest several mechanisms that may contribute to these increased risks. Rapid weight loss associated with GLP-1 medications can lead to decreased bone density due to reduced mechanical load on the skeleton. Additionally, lower caloric intake may result in insufficient levels of calcium, vitamin D, and protein, all crucial for maintaining bone strength. Dr. John Horneff, an associate professor at the University of Pennsylvania, likened the situation to astronauts experiencing bone density loss in a zero-gravity environment.
Official Statements & Responses
Novo Nordisk, the manufacturer of GLP-1 medications, emphasized their commitment to patient safety and collaboration with the U.S. Food and Drug Administration (FDA). Liz Skrbkova, head of U.S. media relations for the company, noted that the known risks and benefits of GLP-1 drugs are reflected in their FDA-approved labeling. She stated, "Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors."
Criticism & Opposition
While the findings raise valid concerns, experts caution against discouraging the use of GLP-1 medications, which have demonstrated significant benefits for blood sugar control and weight loss. Dr. Marilyn Tan, an endocrinologist at Stanford Health Care, highlighted the importance of monitoring patients on these medications for changes in bone health and nutrition.
What's Next
Healthcare providers are encouraged to conduct regular assessments of bone health in patients prescribed GLP-1 medications. Experts recommend that patients ensure adequate nutrition and engage in resistance training to help preserve muscle and bone during weight loss. The ongoing research into the long-term effects of GLP-1 medications will continue to inform best practices for their use.
Verbatim Quotes
- “Both older age and type 2 diabetes are independent risk factors for fragility fractures,” — Dr. Michal Kasher Meron, Endocrinologist
- “These medications should be a jump start toward a healthy lifestyle with diet and exercise, not a substitute,” — Dr. John Gabriel Horneff III, Associate Professor of Orthopedic Surgery
- “It’s “100 percent important” that healthcare providers monitor people taking GLP-1s, says Horneff.” — Dr. John Horneff
The findings underscore the need for careful consideration of bone health in patients using GLP-1 medications, particularly among older adults.
